Alex Zhavoronkov

Alex Zhavoronkov

Signal active

Founder & Chief Executive Officer

Bio

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, and biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe's largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Location

London, England, United Kingdom, Europe

Social

Primary Organization

Insilico Medicine

Insilico Medicine

Founded

2014

Employees

101-250

Industry

Biotechnology, Artificial Intelligence (AI), Health Care, Pharmaceutical

Board and Advisor Roles

0

N/A

Invest in regions

Profile Resume

Alex Zhavoronkov is the Founder & Chief Executive Officer at Insilico Medicine, based in Europe. With a background in Biotechnology, Alex Zhavoronkov has a rich history of leadership and innovation. Alex Zhavoronkov studied Ph.D. Physics @ Moscow State University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.

Recommendation from your interest

N/A

Investment portfolio

Alex Zhavoronkov has made 2 investments. Their Latest investment was Series D - Insilico Medicine on Aug 10, 2022

Number of investment

2

Number of exits

0

Personal investment

2

Annouced DateOrganization NameFunding RoundMoney Raised
Jun 06, 2022
Insilico Medicine Insilico Medicine
Series D - Insilico Medicine
60.0M
Aug 10, 2022
Insilico Medicine Insilico Medicine
Series D - Insilico Medicine
35.0M

Partner investment

0

There is no partner investment available on this profile

Exits

0

There is no exit available on this Profile

Invest in industries